KalVista Pharmaceuticals, Inc.
- Biotech or pharma, therapeutic R&D
KalVista Pharmaceuticals is a biopharmaceutical company discovering, developing and commercializing oral protease inhibitor drugs based on deep expertise in the kallikrein-kinin system. We are open to partnering sebetralstat in select ex-US regions following execution of the Kaken Japan collaboration in April 2025.
For BIO 2025 we are primarily focused on meeting with companies with clinical stage assets available for partnering in immunology, allergy, dermatology therapeutic areas highly complementary to hereditary angioedema that align well with our global commercial footprint, as well more broadly we are open to in-licensing or acquiring clinical stage assets in rare diseases.
**We are not accepting meetings with CROs, CDMOs, or consultants**
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}